P- 26 FIBROSIS FREQUENCY IN A COHORT OF METABOLIC FATTY LIVER DISEASE RISK PATIENTS

Introduction and Objectives

Metabolic fatty liver disease is the most important cause of chronic liver disease with estimated global prevalence of 25% and a latin America prevalence of about 44%. This study aimed to evaluate frequency of fibrosis in risk patients for metabolic liver disease in tertiary center, stratifying grades and presence of risk factors .

Material and Methods

Cross sectional study after informed consent. Clinical examination, bioimpedance and non invasive approach for fibrosis diagnosis by biomarkers and ultrasonography elastography were performed.

Results

Sixty nine patients were included, with 82% women and median age of 63 years. The BMI median was 31 kg/m². Significative fibrosis was present in 30,4% of patients by ultrasonography elastography. Twenty five percent of patients were classified as indeterminated zone fibrosis by FIB 4 and 8,7% with definitely advanced fibrosis risk by Fib4. APRI test results were, respectively, 18,5% and 2,1 %. Fibrosis risk was not associated to steatosis grade but to body corporal fat percentage and serum ferritin.

Conclusions

Our study evidenced approximately a tier of tertiary hospital patients at risk for metabolic fatty liver disease to have fibrosis using ultrasonography elastography. Biomarkers (FIB4 and APRI tests) had a lower frequency for fibrosis identification. Risk factors for fibrosis identified were body fat corporal percentage and serum ferritin.